Last SFr.255.90 CHF
Change Today +0.80 / 0.31%
Volume 818.2K
As of 5:40 AM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (ROG) Snapshot

Open
SFr.258.30
Previous Close
SFr.255.10
Day High
SFr.258.40
Day Low
SFr.254.70
52 Week High
12/3/14 - SFr.295.80
52 Week Low
01/30/14 - SFr.233.60
Market Cap
221.1B
Average Volume 10 Days
3.5M
EPS TTM
SFr.12.68
Shares Outstanding
702.6M
EX-Date
03/6/14
P/E TM
20.2x
Dividend
SFr.7.80
Dividend Yield
3.04%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (ROG)

roche holding ag-genusschein (ROG) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-genusschein (ROG) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-genusschein (ROG) Key Developments

Roche Receives FDA Clearance for Next Generation Cobas MRSA/SA Test

Roche announced that the US Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas® MRSA/SA Test for the early, simultaneous detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (SA) directly from nasal specimens. The cobas® MRSA/SA Test detects both organisms from a single specimen, providing accurate and reliable results for effective prevention and control of MRSA/SA infections. The cobas® MRSA/SA Test, a polymerase chain reaction (PCR)-based assay that runs on the automated cobas® 4800 System, offers labs the most simplified workflow available with a simple de-cap and loading of the primary sample vial onto the cobas® 4800 System. This approach requires less hands-on-time, enabling laboratory staff to spend time on other critical tasks. In addition, this streamlined workflow can help labs reduce costs and improve turnaround time.

F. Hoffmann-La Roche Ltd and Foundation Medicine, Inc. Enter into Strategic Collaboration to Develop New Cancer Treatments

F. Hoffmann-La Roche Ltd. and Foundation Medicine, Inc. entered into a strategic collaboration to enhance the identification and development of novel treatment options for cancer patients. Understanding the comprehensive genomic profile of a cancer patient's disease will enable better personalized healthcare solutions to optimize treatment outcomes for patients. Under the terms of the R&D collaboration agreement, Roche is committing to R&D funding of potentially more than $150 million for a minimum of five years and will contribute its expertise and breadth in oncology. FMI will continue to operate independently and will contribute its experience in the development of comprehensive genomic profiling tests for oncology. The initial focus of the R&D collaboration will be on developing genomic profile tests for cancer immunotherapies and for continuous blood-based monitoring. Roche will be able to utilize FMI's proprietary molecular information platform to standardize clinical trial testing. This aspect of the relationship is designed to enable comparability of clinical trial results for R&D purposes, and ultimately in the clinic. The R&D collaboration and FMI's current and future tests are expected to deliver insights to support development of combination therapies, novel targets, more accurate patient population identification and inclusion in clinical trials, and next generation companion diagnostics. In addition to the R&D collaboration, both parties also agreed to a commercial collaboration agreement designed to broaden FMI's position across clinical and molecular information markets. Specifically, Roche will obtain rights ex-US (under the FMI brand) to existing FMI products, as well as to future co-developed products. In the US, Roche will engage its US medical education team in providing medical information to pathologists.

Roche Licenses Additional EGFR Pathway-Related Intellectual Property to QIAGEN

Roche announced that the company has entered into an agreement with QIAGEN that includes a provision of non-exclusive licenses to recently granted Roche patents pertaining to the detection of mutations in the EGFR pathway (including in the KRAS gene). Financial details were not disclosed. The licenses apply to testing products which detect these mutations using molecular techniques including PCR, next generation sequencing (NGS) and other applications to aid in identification of cancer patients eligible for treatment with certain tyrosine kinase inhibitors. The licenses can be applied to existing and future products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROG:VX SFr.255.90 CHF +0.80

ROG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €130.05 EUR +0.54
General Electric Co $24.59 USD +0.11
Gilead Sciences Inc $107.11 USD +1.57
Merck & Co Inc $62.82 USD +0.33
Sanofi €82.09 EUR -0.86
View Industry Companies
 

Industry Analysis

ROG

Industry Average

Valuation ROG Industry Range
Price/Earnings 20.1x
Price/Sales 4.4x
Price/Book 12.2x
Price/Cash Flow 16.4x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.